Financials data is unavailable for this security.
View more
Year on year Financiere de Tubize SA had revenues remain flat at 0.00, though the company grew net income 3.50% from 85.17m to 88.15m.
| Gross margin | -- |
|---|---|
| Net profit margin | -- |
| Operating margin | -- |
| Return on assets | 9.64% |
|---|---|
| Return on equity | 9.85% |
| Return on investment | 9.85% |
More ▼
Cash flow in EURView more
In 2023, cash reserves at Financiere de Tubize SA fell by 494.00k. However, Cash Flow from Investing totalled 11.30m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 2.05m for operations while cash used for financing totalled 9.75m.
| Cash flow per share | 4.13 |
|---|---|
| Price/Cash flow per share | 31.62 |
| Book value per share | 42.45 |
|---|---|
| Tangible book value per share | 42.45 |
More ▼
Balance sheet in EURView more
| Current ratio | 0.0177 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.0164 |
|---|---|
| Total debt/total capital | 0.0161 |
More ▼
Growth rates in EUR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 12.79% and 3.50%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.73% |
|---|---|
| Div growth rate (5 year) | 11.61% |
| Payout ratio (TTM) | 20.82% |
| EPS growth(5 years) | -20.91 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 106.65 |
More ▼
